The use of adjuvant chemoradiation (aCRT) following surgery for stage III endometrial cancer is increasing, with its use associated with an overall survival (OS) benefit when compared to chemotherapy or radiation alone. This according to a study of 21,027 adult patients with stage III endometrial adenocarcinoma diagnosed from 2004 to 2013: 54% received adjuvant monotherapy (aMT), and 45.6% received aCRT. Researchers found:
• Utilization of aCRT increased over the study period.
• Factors predictive of receiving aCRT included private insurance (OR=1.67), Medicare (OR=1.33), FIGO stage IIIC disease (OR=1.36), lymphovascular space invasion (OR=1.14), and lymph node surgery performed (OR=1.42).
• Median survival in years for aCRT, radiation therapy (RT), and chemotherapy (CT) was 10.3, 7.1, and 5.6, respectively.
• Compared to aMT, aCRT was associated with a decreased risk of death on multivariate analysis (HR=0.62).
Citation: Boothe D, Orton A, Odei B, et al. Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival. [Published online ahead of print March 19, 2016]. Gynecol Oncol. doi:http://dx.doi.org/10.1016/j.ygyno.2016.03.021.
This Week's Must Reads
Must Reads in Gynecologic Cancer
Maternal Factors in Cervical Cancer Prevention, Womens Health Issues; ePub 2019 Jan 10; Charlton, et al
Combined Gynecologic Ca & Pelvic Floor Dysfunction Surgery, Female Pelvic Med Reconstr Surg; ePub 2018 Oct 22; McConnell, et al